1. Netherlands Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Qiagen N.V.

Qiagen N.V.

QIA.DE
Qiagen N.V.DE flagDeutsche Börse
34.12
EUR
+0.05
- -
7.04BMarket Cap
Qiagen N.V.
QIA.DE
(Deutsche Börse)

Recent

price

34.12

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
5.41
5.79
6.2
6.45
6.72
6.37
6.61
6.98
7.43
7.48
9.14
11.07
10.5
9.61
9.64
10.14
10.18
Revenue per Share
0.72
0.48
0.64
0.34
0.58
0.65
0.4
0.2
0.94
-0.2
1.76
2.52
2.08
1.67
0.41
2.06
1.95
Basic EPS, GAAP
0.63
0.61
0.58
0.7
0.95
1
1.22
0.8
1.03
0.27
0.75
2.13
2.78
1.45
2.45
2.17
1.96
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.26
- -
Dividend per Share
3.79
4.25
4.88
5.24
5.64
6.03
6.26
6.16
6.84
5.79
6.48
8.82
10.61
12.03
11.94
13.35
13.6
Book Value per Share
1.84
0.02
0.55
0.39
0.22
0.28
0.61
0.14
0.25
-1.16
-1.43
0.58
2.79
3.94
4.08
3.35
1.3
Tangible Book Value per Share
201
202
202
202
200
201
202
203
202
204
205
203
204
204
205
206
206
Basic Weighted Avg Shares
1,087
1,170
1,254
1,302
1,345
1,281
1,338
1,418
1,502
1,526
1,870
2,252
2,142
1,965
1,978
2,090
2,099
Sales/Revenue/Turnover
17.34
8.51
13.54
4.86
12.02
14.01
7.39
17.74
20.19
20.55
28.74
29.22
26.91
22.66
10.11
24.9
24.38
Operating Margin (%)
143
167
198
199
201
191
213
216
206
231
205
215
208
205
203
194
201
Depreciation Expense
144
96
130
69
116
130
80
40
190
-41
359
513
423
341
84
425
402
Net Income, GAAP
16.64
1.31
10.76
- -
2.06
4.7
- -
64.68
15.66
- -
18.27
18.09
17.44
20.59
31
13.34
11.91
Effective Tax Rate (%)
13.27
8.21
10.32
5.31
8.65
10.16
6.01
2.85
12.68
-2.72
19.2
22.77
19.76
17.37
4.23
20.33
19.16
Profit Margin (%)
976
294
726
584
717
693
729
1,323
1,183
619
1,052
592
1,419
1,068
918
1,483
1,061
Working Capital
797
446
846
845
1,041
1,049
1,067
1,758
1,671
1,421
1,880
1,094
1,472
922
936
1,784
1,647
LT Debt
2,476
2,558
2,724
2,724
2,658
2,568
2,607
2,541
2,635
2,537
2,798
3,097
3,467
3,808
3,567
3,778
3,332
Total Equity
4.73
2.98
4.48
- -
4.25
4.57
- -
2.22
5.59
- -
9.75
11
9.14
6.62
2.65
8.43
9.24
Return on Invested Capital (%)
10.55
7.89
9.08
- -
7.3
7.26
- -
2.17
7.53
- -
13.51
15.85
12.08
9.55
2.86
10.64
10.4
Return on Capital (%)
20.9
11.85
14.02
6.75
10.65
11.12
6.49
3.21
14.46
-3.23
28.66
32.86
21.39
14.77
3.4
16.34
15.16
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
500
29
- -
LT Borrowings
1,628
1,654
1,647
LT Finance Leases
- -
129
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
206
206
206
Market Capitalization
9,726
10,044
8,278

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
2,531
1,995
1,540
Cash, Cash Equivalents & STI
1,690
1,099
646
Accounts Receivable, Net
376
403
397
Inventories
290
302
310
Total Current Liabilities
973
512
479
Payables & Accruals
474
310
479
ST Debt
500
29
- -
Deferred Revenue
- -
79
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.13%
6.41%
5.91%
Free Cash Flow
34.24%
44.65%
-10.97%
Net Income, GAAP
-46.62%
67.74%
408.28%
Sales/Revenue/Turnover
5.41%
2.72%
5.65%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
459
496
502
521
1,978
2025
483
534
533
540
2,090
2026
492
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.38
-0.87
0.46
0.43
0.41
2025
0.42
0.47
0.63
0.52
2.06
2026
0.33
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
0.26
2026
- -
- -
- -
- -
- -
Similar Companies
NanoRepro AG (NN6.DE)
Clearbridge Health Limited (1H3.SI)
Insight Molecular Diagnostics Inc. (0KCC.L)
Australian Clinical Labs Limited (ACL.AX)
PT Prodia Widyahusada Tbk (PRDA.JK)
Global WholeHealth Partners Corporation (GWHP)
Business
Qiagen N.V. provides Sample to Insight solutions that enable molecular testing, preanalytical sample technologies and assay products for applied markets worldwide. The company offers sample preparation kits and consumables for DNA, RNA and protein isolation; molecular diagnostics assays including real-time PCR, next-generation sequencing and immunoassay systems such as QuantiFERON and QIAstat-Dx; bioinformatics software and knowledge bases for data analysis; and automation instruments like QIAsymphony for high-throughput workflows. It serves customers in molecular diagnostics for human healthcare, life sciences research, pharma and biotech, applied testing for forensics, veterinary and food safety; operates over 35 locations globally with more than 5,700 employees; founded in 1984 and headquartered in Venlo, Netherlands. Qiagen announces the acquisition of Parse Biosciences to expand into the single-cell sequencing market and capture AI-driven growth; launches new instruments including QIAsymphony Connect and advances three Sample technologies systems in 2025-2026; approves a $500 million synthetic share repurchase program for completion in early January 2026, advancing toward $1 billion in shareholder returns by 2028; and raises FY 2025 adjusted diluted EPS target to about $2.38 CER following Q3 results exceeding outlook.